Drug firm Aurobindo Pharma on Friday said its arm Helix Healthcare B V, Netherlands has entered into an agreement with Chinese firm Shanghai LongJin Investment Company and Sveva Capitals, Hongkong to form a JV firm, Longxiang Pharma Taizhou Co Ltd in China.
The joint venture is for development, manufacturing, marketing and sale of pharmaceutical products for China, excluding Taiwan, Hongkong and Macau, Aurobindo Pharma said in a filing to the BSE.
While Helix will have 57 per cent shareholding in the JV, LongJin will have 40 per cent and Sveva will have 3 per cent shareholding, it added.
"Commencement of commercial production of JVC is expected during 2022-23," Aurobindo Pharma said.
Helix has the right to appoint three directors, while LongJin has the right to appoint two directors in JVC, it added.
Shares of Aurobindo Pharma closed at Rs 600.70 per scrip on the BSE, up 1.64 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app